Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | MAOA | P21397 | 1/20 | 0.80 |
| ▸ | SCN1A | P35498 | 1/20 | 0.80 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.80 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theracys SCHEMBL18648964 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL367470 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL328884 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL116803 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL13196454 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL16922152 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL11415956 | 0.99 | KCNH2 (0.78) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL6716416 | 0.99 | SLC6A2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL8958743 | 0.94 | KCNH2 (0.72) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Cocaine SCHEMBL8050369 | 0.93 | KCNH2 (0.93) | KCNH2SLC6A2SLC6A4SLC6A3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121486-A1 | COMPOSITIONS AND COMPOUNDS FOR TREATING COVID-19 | INTERNATIONAL PATENT HOLDINGS LLC (KN) | 2023-06-29 | — | — | WO | claimed |
| EP-3891505-B1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2022-11-30 | — | — | EP | claimed |
| US-8067401-B2 | Compounds and compositions for treating infection | INTERNATIONAL PATENT HOLDINGS LLC (KN) | 2011-11-29 | — | — | US | claimed |
| US-20090069277-A1 | Compounds and compositions for treating infection | INTERNATIONAL PATENT HOLDINGS LTD. | 2009-03-12 | — | — | US | claimed |
| EP-4747639-A2 | BETA-GALACTOSIDASE ENZYME-BASED IMMUNOASSAY | Abbott Diagnostics Scarborough, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4623304-A1 | DERIVATISATION AGENT FOR LASER DESORPTION IONIZATION MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| EP-4623289-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | F. Hoffmann-La Roche AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025018987-A2 | ΒETA-GALACTOSIDASE ENZYME-BASED IMMUNOASSAY | ABBOTT DIAGNOSTICS SCARBOROUGH, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024110385-A1 | DERIVATISATION AGENT FOR LASER DESORPTION IONIZATION MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024110422-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-30 | — | — | WO | disclosed |
| EP-4154010-A1 | REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-8697660-B2 | Compounds and compositions for treating infection | INTERNATIONAL PATENT HOLDINGS LLC | 2014-04-15 | — | — | US | disclosed |
| US-6350758-B1 | NOVEL ANALOGS OF COCAINE, ENHANCED ANALGESIC AND/OR VASOCONSTRICTIVE PROPERTIES, INHIBIT THE UPTAKE OF DOPAMINE OR SEROTONIN SO USEFUL FOR TREATING PARKINSON'S DISEASE, DEPRESSION, OR OBESITY, TREATING COCAINE ABUSE, COCAINE | GEORGETOWN UNIVERSITY | 2002-02-26 | — | — | US | disclosed |
| US-6054127-A | A THERAPEUTIC TREATMENT FOR COCAINE ADDICTION; THE CONJUGATE CAPABLE OF STIMULATING THE PRODUCTION OF ANTI-HAPTEN ANTIBODIES; A THERAPEUTIC IMMUNIZATION REGIMEN ELICITS ANTI-DRUG ANTIBODIES | IMMULOGIC PHARMACEUTICAL CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| EP-0944626-A1 | TROPANE DERIVATIVES AND METHOD FOR THEIR SYNTHESIS | GEORGETOWN UNIVERSITY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998024788-A1 | TROPANE DERIVATIVES AND METHOD FOR THEIR SYNTHESIS | GEORGETOWN UNIVERSITY (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5391744-A | Enhanced analgesic and vasoconstrictive properties | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1995-02-21 | — | — | US | disclosed |
| US-4197237-A | Antibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereof | SYVA COMPANY (US) | 1980-04-08 | — | — | US | disclosed |
| US-4123431-A | Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds and derivatives thereof | SYVA COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4045420-A | Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof | SYVA COMPANY (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069277-A1 | Compounds and compositions for treating infection | RPN2, LSS, CLIC4 | KCNH2 984/4885SLC6A2 2461/4885SLC6A4 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.